Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ENANTA PHARMACEUTICALS INC (ENTA)

Enanta loses UPC patent case against Pfizer; court finds '265 Patent invalid

Negative Impact 3 of 5 legal/regulatory Written later

Enanta Pharmaceuticals said the Unified Patent Court of the European Union ruled on October 29, 2026 that its European Patent No. EP 4 051 265 is invalid and that its infringement action against Pfizer was unfounded. The ruling ends Enanta's infringement claim over Pfizer's Paxlovid sales in the 18 participating EU member states, which the filing does not quantify.

Key points

  • Court decision released October 29, 2026, following a hearing held September 29, 2026
  • UPC concluded the '265 Patent is invalid, responding to Pfizer's counterclaim for revocation
  • Court also found the infringement action unfounded in light of the validity decision
  • Filing does not state any financial impact, damages, or next steps

The filing

CompanyENANTA PHARMACEUTICALS INC (ENTA)
Form8-K, current report
Filed with the SECOct 29, 2026, 4:05 PM ET
Accession number0001193125-26-437774

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.